Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2006

01-08-2006 | Article

Diabetes-associated mitochondrial DNA mutation A3243G impairs cellular metabolic pathways necessary for beta cell function

Authors: P. B. M. de Andrade, B. Rubi, F. Frigerio, J. M. W. van den Ouweland, J. A. Maassen, P. Maechler

Published in: Diabetologia | Issue 8/2006

Login to get access

Abstract

Aims/hypothesis

Mitochondrial DNA (mtDNA) mutations cause several diseases, including mitochondrial inherited diabetes and deafness (MIDD), typically associated with the mtDNA A3243G point mutation on tRNALeu gene. The common hypothesis to explain the link between the genotype and the phenotype is that the mutation might impair mitochondrial metabolism expressly required for beta cell functions. However, this assumption has not yet been tested.

Methods

We used clonal osteosarcoma cytosolic hybrid cells (namely cybrids) harbouring mitochondria derived from MIDD patients and containing either exclusively wild-type or mutated (A3243G) mtDNA. According to the importance of mitochondrial metabolism in beta cells, we studied the impact of the mutation on key parameters by comparing stimulation of these cybrids by the main insulin secretagogue glucose and the mitochondrial substrate pyruvate.

Results

Compared with control mtDNA from the same patient, the A3243G mutation markedly modified metabolic pathways leading to a high glycolytic rate (2.8-fold increase), increased lactate production (2.5-fold), and reduced glucose oxidation (−83%). We also observed impaired NADH responses (−56%), negligible mitochondrial membrane potential, and reduced, only transient ATP generation. Moreover, cybrid cells carrying patient-derived mutant mtDNA exhibited deranged cell calcium handling with increased cytosolic loads (1.4-fold higher), and elevated reactive oxygen species (2.6-fold increase) under glucose deprivation.

Conclusions/interpretation

The present study demonstrates that the mtDNA A3243G mutation impairs crucial metabolic events required for proper cell functions, such as coupling of glucose recognition to insulin secretion.
Literature
1.
2.
Buchet K, Godinot C (1998) Functional F1-ATPase essential in maintaining growth and membrane potential of human mitochondrial DNA-depleted rho degrees cells. J Biol Chem 273:22983–22989PubMedCrossRef
3.
Kadowaki T, Kadowaki H, Mori Y et al (1994) A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330:962–968PubMedCrossRef
4.
van den Ouweland JM, Lemkes HH, Ruitenbeek W et al (1992) Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1:368–371PubMedCrossRef
5.
Maechler P, Wollheim CB (2001) Mitochondrial function in normal and diabetic beta-cells. Nature 414:807–812PubMedCrossRef
6.
Dunbar DR, Moonie PA, Zeviani M, Holt IJ (1996) Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids. Hum Mol Genet 5:123–129PubMedCrossRef
7.
van den Ouweland JM, Maechler P, Wollheim CB, Attardi G, Maassen JA (1999) Functional and morphological abnormalities of mitochondria harbouring the tRNA(Leu)(UUR) mutation in mitochondrial DNA derived from patients with maternally inherited diabetes and deafness (MIDD) and progressive kidney disease. Diabetologia 42:485–492PubMedCrossRef
8.
Maassen JA, Janssen GM, t Hart LM (2005) Molecular mechanisms of mitochondrial diabetes (MIDD). Ann Med 37:213–221PubMedCrossRef
9.
Lynn S, Borthwick GM, Charnley RM, Walker M, Turnbull DM (2003) Heteroplasmic ratio of the A3243G mitochondrial DNA mutation in single pancreatic beta cells. Diabetologia 46:296–299PubMed
10.
Maassen JA, van Essen E, van den Ouweland JM, Lemkes HH (2001) Molecular and clinical aspects of mitochondrial diabetes mellitus. Exp Clin Endocrinol Diabetes 109:127–134PubMedCrossRef
11.
Rorsman P (1997) The pancreatic beta-cell as a fuel sensor: an electrophysiologist’s viewpoint. Diabetologia 40:487–495PubMedCrossRef
12.
Maechler P (2002) Mitochondria as the conductor of metabolic signals for insulin exocytosis in pancreatic beta-cells. Cell Mol Life Sci 59:1803–1818PubMedCrossRef
13.
Velho G, Byrne MM, Clement K et al (1996) Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes 45:478–487PubMedCrossRef
14.
Brandle M, Lehmann R, Maly FE, Schmid C, Spinas GA (2001) Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation. Diabetes Care 24:1253–1258PubMedCrossRef
15.
Maassen JA, T Hart LM, Van Essen E et al (2004) Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 53(Suppl 1):S103–S109PubMedCrossRef
16.
17.
Rubi B, del Arco A, Bartley C, Satrustegui J, Maechler P (2004) The malate-aspartate NADH shuttle member Aralar1 determines glucose metabolic fate, mitochondrial activity, and insulin secretion in beta cells. J Biol Chem 279:55659–55666PubMedCrossRef
18.
de Andrade PB, Casimir M, Maechler P (2004) Mitochondrial activation and the pyruvate paradox in a human cell line. FEBS Lett 578:224–228PubMedCrossRef
19.
Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P (2004) Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 145:667–678PubMedCrossRef
20.
Maechler P, Wang H, Wollheim CB (1998) Continuous monitoring of ATP levels in living insulin secreting cells expressing cytosolic firefly luciferase. FEBS Lett 422:328–332PubMedCrossRef
21.
Rubi B, Ishihara H, Hegardt FG, Wollheim CB, Maechler P (2001) GAD65-mediated glutamate decarboxylation reduces glucose-stimulated insulin secretion in pancreatic beta cells. J Biol Chem 276:36391–36396PubMedCrossRef
22.
Rubi B, Ljubicic S, Pournourmohammadi S et al (2005) Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 280:36824–36832PubMedCrossRef
23.
Appleby RD, Porteous WK, Hughes G et al (1999) Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA. Eur J Biochem 262:108–116PubMedCrossRef
24.
Narushima M, Kobayashi N, Okitsu T et al (2005) A human beta-cell line for transplantation therapy to control type 1 diabetes. Nat Biotechnol 23:1274–1282PubMedCrossRef
25.
Silvestri G, Moraes CT, Shanske S, Oh SJ, DiMauro S (1992) A new mtDNA mutation in the tRNA(Lys) gene associated with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 51:1213–1217PubMed
26.
Brini M, Pinton P, King MP, Davidson M, Schon EA, Rizzuto R (1999) A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 5:951–954PubMedCrossRef
27.
28.
Beretta S, Mattavelli L, Sala G et al (2004) Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain 127:2183–2192PubMedCrossRef
29.
Sandhu JK, Sodja C, McRae K et al (2005) Effects of nitric oxide donors on cybrids harbouring the mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) A3243G mitochondrial DNA mutation. Biochem J 391:191–202PubMedCrossRef
30.
Vives-Bauza C, Gonzalo R, Manfredi G, Garcia-Arumi E, Andreu AL (2006) Enhanced ROS production and antioxidant defenses in cybrids harbouring mutations in mtDNA. Neurosci Lett 391:136–141PubMedCrossRef
31.
Herst PM, Tan AS, Scarlett DJ, Berridge MV (2004) Cell surface oxygen consumption by mitochondrial gene knockout cells. Biochim Biophys Acta 1656:79–87PubMedCrossRef
32.
Park SY, Chang I, Kim JY et al (2004) Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem 279:7512–7520PubMedCrossRef
33.
Vergani L, Floreani M, Russell A et al (2004) Antioxidant defences and homeostasis of reactive oxygen species in different human mitochondrial DNA-depleted cell lines. Eur J Biochem 271:3646–3656PubMedCrossRef
34.
Miranda S, Foncea R, Guerrero J, Leighton F (1999) Oxidative stress and upregulation of mitochondrial biogenesis genes in mitochondrial DNA-depleted HeLa cells. Biochem Biophys Res Commun 258:44–49PubMedCrossRef
35.
Floreani M, Napoli E, Martinuzzi A et al (2005) Antioxidant defences in cybrids harboring mtDNA mutations associated with Leber’s hereditary optic neuropathy. Febs J 272:1124–1135PubMedCrossRef
36.
Trifunovic A, Hansson A, Wredenberg A et al (2005) Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production. Proc Natl Acad Sci U S A 102:17993–17998PubMedCrossRef
37.
Ballinger SW, Shoffner JM, Hedaya EV et al (1992) Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. Nat Genet 1:11–15PubMedCrossRef
38.
De Block CE, De Leeuw IH, Maassen JA, Ballaux D, Martin JJ (2004) A novel 7301-bp deletion in mitochondrial DNA in a patient with Kearns–Sayre syndrome, diabetes mellitus, and primary amenorrhoea. Exp Clin Endocrinol Diabetes 112:80–83PubMedCrossRef
39.
van den Ouweland JM, de Klerk JB, van de Corput MP et al (2000) Characterization of a novel mitochondrial DNA deletion in a patient with a variant of the Pearson marrow–pancreas syndrome. Eur J Hum Genet 8:195–203PubMedCrossRef
40.
Silva JP, Kohler M, Graff C et al (2000) Impaired insulin secretion and beta-cell loss in tissue-specific knockout mice with mitochondrial diabetes. Nat Genet 26:336–340PubMedCrossRef
41.
Soejima A, Inoue K, Takai D et al (1996) Mitochondrial DNA is required for regulation of glucose-stimulated insulin secretion in a mouse pancreatic beta cell line, MIN6. J Biol Chem 271:26194–26199PubMedCrossRef
42.
Kennedy ED, Maechler P, Wollheim CB (1998) Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes 47:374–380PubMedCrossRef
43.
Tsuruzoe K, Araki E, Furukawa N et al (1998) Creation and characterization of a mitochondrial DNA-depleted pancreatic beta-cell line: impaired insulin secretion induced by glucose, leucine, and sulfonylureas. Diabetes 47:621–631PubMedCrossRef
Metadata
Title
Diabetes-associated mitochondrial DNA mutation A3243G impairs cellular metabolic pathways necessary for beta cell function
Authors
P. B. M. de Andrade
B. Rubi
F. Frigerio
J. M. W. van den Ouweland
J. A. Maassen
P. Maechler
Publication date
01-08-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0301-9

Other articles of this Issue 8/2006

Diabetologia 8/2006 Go to the issue

Article

Understanding of diabetes prevention studies: questionnaire survey of professionals in diabetes care

Article

Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY

Article

HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden

Article

Mitochondrial dysfunction induces aberrant insulin signalling and glucose utilisation in murine C2C12 myotube cells

Article

Reductions in caloric intake and early postnatal growth prevent glucose intolerance and obesity associated with low birthweight

Article

Suitability of human juvenile pancreatic islets for clinical use
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits